Literature DB >> 20736363

Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss.

Alicia M Cole1, Kevin Myant, Karen R Reed, Rachel A Ridgway, Dimitris Athineos, Gijs R Van den Brink, Vanesa Muncan, Hans Clevers, Alan R Clarke, Peter Sicinski, Owen J Sansom.   

Abstract

Inactivation of the Apc gene is recognized as the key early event in the development of sporadic colorectal cancer (CRC), where its loss leads to constitutive activation of β-catenin/T-cell factor 4 signaling and hence transcription of Wnt target genes such as c-Myc. Our and other previous studies have shown that although cyclin D1 is required for adenoma formation, it is not immediately upregulated following Apc loss within the intestine, suggesting that proliferation following acute Apc loss may be dependent on another D-type cyclin. In this study, we investigated the expression and functional relevance of cyclin D2 following Apc loss in the intestinal epithelium. Cyclin D2 is upregulated immediately following Apc loss, which corresponded with a significant increase in cyclin-dependent kinase 4 (CDK4) and hyperphosphorylated Rb levels. Deficiency of cyclin D2 resulted in a reduction in enterocyte proliferation and crypt size within Apc-deficient intestinal epithelium. Moreover, cyclin D2 dramatically reduced tumor growth and development in Apc(Min/+) mice. Importantly, cyclin D2 knockout did not affect proliferation of normal enterocytes, and furthermore, CDK4/6 inhibition also suppressed the proliferation of adenomatous cells and not normal cells from Apc(Min/+) mice. Taken together, these results indicate that cyclin D-CDK4/6 complexes are required for the efficient proliferation of cells with deregulated Wnt signaling, and inhibiting this complex may be an effective chemopreventative strategy in CRC. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20736363      PMCID: PMC2974087          DOI: 10.1158/0008-5472.CAN-10-0315

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Crypt-restricted proliferation and commitment to the Paneth cell lineage following Apc loss in the mouse intestine.

Authors:  Pauline Andreu; Sabine Colnot; Cécile Godard; Sophie Gad; Philippe Chafey; Michiko Niwa-Kawakita; Pierre Laurent-Puig; Axel Kahn; Sylvie Robine; Christine Perret; Béatrice Romagnolo
Journal:  Development       Date:  2005-02-16       Impact factor: 6.868

Review 2.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

3.  Mutual requirement of CDK4 and Myc in malignant transformation: evidence for cyclin D1/CDK4 and p16INK4A as upstream regulators of Myc.

Authors:  K Haas; P Staller; C Geisen; J Bartek; M Eilers; T Möröy
Journal:  Oncogene       Date:  1997-07-10       Impact factor: 9.867

4.  Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27.

Authors:  C Bouchard; K Thieke; A Maier; R Saffrich; J Hanley-Hyde; W Ansorge; S Reed; P Sicinski; J Bartek; M Eilers
Journal:  EMBO J       Date:  1999-10-01       Impact factor: 11.598

5.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.

Authors:  O Tetsu; F McCormick
Journal:  Nature       Date:  1999-04-01       Impact factor: 49.962

Review 6.  Control of cell proliferation by Myc family genes.

Authors:  M Eilers
Journal:  Mol Cells       Date:  1999-02-28       Impact factor: 5.034

7.  c-Myc regulates cell size and ploidy but is not essential for postnatal proliferation in liver.

Authors:  Esther Baena; Alberto Gandarillas; Mireia Vallespinós; Jennifer Zanet; Oriol Bachs; Clara Redondo; Isabel Fabregat; Carlos Martinez-A; Ignacio Moreno de Alborán
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-27       Impact factor: 11.205

8.  Identification of FAP locus genes from chromosome 5q21.

Authors:  K W Kinzler; M C Nilbert; L K Su; B Vogelstein; T M Bryan; D B Levy; K J Smith; A C Preisinger; P Hedge; D McKechnie
Journal:  Science       Date:  1991-08-09       Impact factor: 47.728

9.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.

Authors:  M Shtutman; J Zhurinsky; I Simcha; C Albanese; M D'Amico; R Pestell; A Ben-Ze'ev
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

10.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Authors:  David W Fry; Patricia J Harvey; Paul R Keller; William L Elliott; Maryanne Meade; Erin Trachet; Mudher Albassam; XianXian Zheng; Wilbur R Leopold; Nancy K Pryer; Peter L Toogood
Journal:  Mol Cancer Ther       Date:  2004-11       Impact factor: 6.261

View more
  45 in total

Review 1.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

2.  Wnt Signaling in Normal and Malignant Stem Cells.

Authors:  Dheeraj Bhavanasi; Peter S Klein
Journal:  Curr Stem Cell Rep       Date:  2016-10-13

3.  PTE, a novel module to target Polycomb Repressive Complex 1 to the human cyclin D2 (CCND2) oncogene.

Authors:  Sarina R Cameron; Soumyadeep Nandi; Tatyana G Kahn; Juan I Barrasa; Per Stenberg; Yuri B Schwartz
Journal:  J Biol Chem       Date:  2018-08-01       Impact factor: 5.157

Review 4.  Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers.

Authors:  Sameh Mikhail; Christopher Albanese; Michael J Pishvaian
Journal:  Am J Pathol       Date:  2015-03-05       Impact factor: 4.307

5.  Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer.

Authors:  Seung-Chul Pack; Hye-Ran Kim; Sang-Woo Lim; Hwan-Young Kim; Jung-Yun Ko; Ki-Sang Lee; David Hwang; Seong-Il Park; Hoon Kang; Sang-Wook Park; Gun-Young Hong; Se-Min Hwang; Myung-Geun Shin; Soong Lee
Journal:  Int J Colorectal Dis       Date:  2012-09-19       Impact factor: 2.571

6.  A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.

Authors:  Malini Menon; Richard Elliott; Leandra Bowers; Nicolae Balan; Rumana Rafiq; Sara Costa-Cabral; Felix Munkonge; Ines Trinidade; Roderick Porter; Andrew D Campbell; Emma R Johnson; Christina Esdar; Hans-Peter Buchstaller; Birgitta Leuthner; Felix Rohdich; Richard Schneider; Owen Sansom; Dirk Wienke; Alan Ashworth; Christopher J Lord
Journal:  Sci Rep       Date:  2019-01-17       Impact factor: 4.379

7.  Impact of deleterious passenger mutations on cancer progression.

Authors:  Christopher D McFarland; Kirill S Korolev; Gregory V Kryukov; Shamil R Sunyaev; Leonid A Mirny
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-06       Impact factor: 11.205

8.  APC controls asymmetric Wnt/β-catenin signaling and cardiomyocyte proliferation gradient in the heart.

Authors:  Bo Ye; Ning Hou; Lu Xiao; Yifan Xu; James Boyer; Haodong Xu; Faqian Li
Journal:  J Mol Cell Cardiol       Date:  2015-10-19       Impact factor: 5.000

9.  Analysis of inflammatory and lipid metabolic networks across RAW264.7 and thioglycolate-elicited macrophages.

Authors:  Mano R Maurya; Shakti Gupta; Xiang Li; Eoin Fahy; Ashok R Dinasarapu; Manish Sud; H Alex Brown; Christopher K Glass; Robert C Murphy; David W Russell; Edward A Dennis; Shankar Subramaniam
Journal:  J Lipid Res       Date:  2013-06-17       Impact factor: 5.922

10.  D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL.

Authors:  Yoon Jong Choi; Borja Saez; Lars Anders; Per Hydbring; Joanna Stefano; Nickolas A Bacon; Colleen Cook; Ilona Kalaszczynska; Sabina Signoretti; Richard A Young; David T Scadden; Piotr Sicinski
Journal:  Dev Cell       Date:  2014-07-31       Impact factor: 12.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.